Smith & Nephew PLC

SN.

Equity

ISIN GB0009223206 / Valor 1103058

LSE London Stock Exchange, SETS (2026-03-31)

GBP 11.85-1.29%

Smith & Nephew PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Smith & Nephew PLC is a global medical technology company specializing in products and solutions for the repair, regeneration, and replacement of soft and hard tissues. The company operates across several key areas, including Sports Medicine, Ear, Nose & Throat (ENT), and Advanced Wound Management, providing instruments and devices that address diverse clinical needs. Through strategic acquisitions such as Herts Pharmaceuticals, Osiris Therapeutics, Ceterix Orthopaedics, Leaf Patient Monitoring System, and Brainlab's Orthopaedic Joint Reconstruction Business, Smith & Nephew has expanded its portfolio to include pharmaceutical and skincare products, as well as advanced patient monitoring technologies. These expansions enable the company to enhance its research and development capabilities, fostering innovation to meet the evolving demands of the global healthcare market.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

9.22%1Y

5.61%3Y

-14.3%5Y

Performance

28.5%1Y

25.0%3Y

25.4%5Y

Volatility